Research highlights a growing trend of prescribing weight-loss drugs once limited to adults, now reaching children aged 8 to 11. A study led by New York University investigates the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among these young children struggling with obesity.
Utilizing data from over 3.5 million children within the Epic Cosmos electronic health record network, researchers tracked prescription trends from January 2019 to June 2026. Findings reveal a notable surge in GLP-1 prescriptions, escalating from a mere 0.03% of the target group in 2019 to 9.3% by 2026, marking a 310-fold increase.
Despite the dramatic rise, only 0.6% of the children in the study had been prescribed a GLP-1 medication by the end of the period. This uptick corresponds with heightened interest in GLP-1 drugs for obesity treatment, even though FDA approval is limited to adolescents aged 12 and up. No current approvals exist for children under 12, though guidelines allow for exceptions in severe cases.
The study reveals that these medications are typically reserved for children facing significant health risks. Among GLP-1 users, 94% had severe obesity compared to 52% who did not. Lead researcher Dr. Babak J. Orandi from NYU emphasizes lifestyle approaches as primary interventions. “Diet, physical activity, and behavioral support are the foundation,” Orandi states, recommending GLP-1 drugs as an addition rather than a standalone treatment.
Medications should come into consideration when a child experiences related health issues or when lifestyle changes prove insufficient. According to Orandi, such signals warrant discussions with pediatricians. Distinguished patterns also emerge among demographics; older children and girls are more frequently prescribed these medications.
Furthermore, children from less vulnerable communities have higher access to prescriptions, suggesting potential inequalities in obesity treatment access. The study warns these disparities could widen as more pediatric indications arise.
Researchers note the limitations of using electronic health records, which may not accurately reflect if prescriptions are filled, adhered to, or sustained over time. Additionally, the data might not represent all U.S. health systems.
More research is necessary to understand long-term impacts. While early data appears promising, Orandi stresses the need for longer follow-ups. Balancing risks and benefits remains crucial, given the known dangers of untreated childhood obesity, such as type 2 diabetes and joint issues.
Reversing obesity in childhood brings significant health benefits into adulthood. Orandi notes, “Children achieving healthier weights by adulthood face the same heart health risks as peers never experiencing obesity.” This reversibility presents a strong case for treating obesity early.
Leave a Reply